Obviously my own opinion here, but I don’t believe POTUS
Obviously my own opinion here, but I don’t believe POTUS is taking HCQ. It’s been shown to be ineffective and dangerous to people similar to him. His physician knows this.
There are reasons he’d push it which should be obvious to anybody with even a modicum of investing experience. A little research on the company that owns and manufactures it is quite enlightening.
There are also reasons he, the FDA, NIH and CDC aren’t even mentioning CYDY, and its starting to look like we will get our break from another nation taking the lead. Once word gets out it will eventually, and begrudgingly be approved here.
Frustrating for us certainly, but absolutely immoral for those afflicted with the virus.
3
2
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
AIM-T1: A Game-Changer for Electronics Manufacturing You ever wonder how a single gizmo could shake up the entire electronics manufacturing world? Well, A.I.Matics' AIM-T1 has done just that by snagging two coveted CES Innovation Awards for 2027. In the cutthroat arenas of Artificial Intelligence and Construction & Industrial Tech, this platform's getting the spotlight...
Continue Reading
CPT Changes: A New Era for Dermatology? Get this: the American Medical Association's revisions to the CPT codes could be just the spark LASEROPTEK's been waiting for. Landing on the desk is the 2027 Current Procedural Terminology (CPT) code set which clarifies how docs report targeted UVB laser treatments. We're talking about codes 96920–96922, now clear as crystal,...
Continue Reading
Gold Again: The Bright Start 529 Legacy Shining brightly for the eighth consecutive time, Illinois' Bright Start 529 College Savings Plan has snagged yet another Gold rating from Morningstar. That's no small feat folks, especially in a landscape where nine Gold ratings grace the entire roster of 529 plans in the country. Illinois' treasure chest plan under Treasurer...
Continue Reading
A Spotlight on Legal Excellence In the tough-as-nails world of legal battles, a select few rise above the rest, but it's not every day you see three folks from the same shop getting the nod as MVPs. That's the story coming out of Greenberg Traurig, where shareholders Gregory A. Fishman, Michael J. Thomas, and David B. Weinstein made the cut for the 2026 Law360 MVP honors....
Continue Reading
A Celebration of Achievements in South Florida Nothing signifies success like a room full of applause and a shiny award, especially when it comes from a community as influential as South Florida's construction scene. This past October, Greenberg Traurig, a heavy hitter in the legal sphere, clinched its title as the Law Firm of the Year from the Latin Builders Association...
Continue Reading
Pushing the Envelope on AI Control Alright, AI wonks, the Responsible AI Institute just introduced a new sheriff in town. It's called the TrustX Assurance Lab, and it was rolled out during RAISE 2026. We're talking about an independent setup designed to answer whether autonomous AI can stay within its limits. Who's involved? A lot of brainpower from member organizations...
Continue Reading
Lindian Resources Drives New Deal in Rare Earths Ah, the sweet smell of another strategic move in the resources game. Lindian Resources Limited is strutting its stuff down under by securing a binding offtake for a hefty 30,000 tonnes of Monazite Concentrate. Now, that's a weighty lift in the world of rare earths, and it kicks off just in time for their December production...
Continue Reading
Cracks Surfacing at ResMed? Alright, folks, ResMed Inc. (NYSE: RMD) is facing a bit of heat these days. We're talking about a shareholder alert as Levi & Korsinsky, noted legal hounds when it comes to financial misconduct, have decided to dig deep into ResMed. They're looking to uncover any possible breaches of fiduciary duties by some of the top brass at this sleep apnea...
Continue Reading
Unpacking Stellus Capital's Latest Quarter Boy, Stellus Capital sure knows how to keep us on our toes. In a landscape where many are still reeling from the latest market tremors, they post some solid Q3 numbers for September 30, 2026. Not without its hiccups, but hey, who isn’t stumbling a bit right now? Financial Snapshot: Stability Amidst Uncertainty Stellus reported...
Continue Reading
Speeding Up Diagnostics: A Major Leap Forward In a world where every second counts, LG Energy Solution strikes gold with their latest innovation, Re.Pulse. CES Innovation Awards 2027 has honored LG for this slick piece of tech that trims down battery diagnosis time from a snail's pace seven hours to a lightning-fast 10 minutes. It's not just about speed—it’s also...
Continue Reading
Top 5 Most Recently Viewed Articles
Leading the Way in Transplant Excellence NYU Langone Health has established itself as a premier health institution, particularly noted for its outstanding kidney, liver, and lung transplant programs. The dedication to providing top-tier care is evident in the consistently high quality outcomes reported by the NYU Langone Transplant Institute. This institute is known for...
Continue Reading
Understanding Dollar Tree's Recent Options Trends Investors are witnessing a notable shift toward a bullish stance on Dollar Tree, indicating that significant developments could be on the horizon. This emerging interest from well-capitalized investors is critical for market players to consider. Recent observations of the options landscape show that this isn't merely...
Continue Reading
Short Interest Surge: A Red Flag or Opportunity? Short interest isn't just a bunch of numbers drizzled over your trading screen; it's cold, hard emotion boiling beneath the surface. When it comes to PNC Financial Services Group Inc (NYSE:PNC), we're staring at a 13.24% spike since the last report, amounting to a whopping 6.22 million shares sold short. That’s a mere...
Continue Reading
Azazie Brings a Unique Bridal Experience to Los Angeles Azazie, a renowned direct-to-consumer bridal and special occasion retailer, is thrilled to announce an exclusive one-day pop-up event in Los Angeles. This pop-up promises to be a delightful opportunity for brides-to-be, bridal parties, and fashion enthusiasts to explore a stunning collection of wedding gowns and...
Continue Reading
Positive Phase II Results for Icovamenib in Type 2 Diabetes Biomea Fusion, Inc., a clinical-stage company focused on innovative treatments for diabetes and obesity, recently shared encouraging findings from its Phase II COVALENT-111 study, which examined the effects of icovamenib in type 2 diabetes (T2D) patients. This pivotal research provides vital insights into the...
Continue Reading